Voyager Therapeutics to Participate in Key Conference
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a pioneering biotechnology company focusing on genetic solutions for neurological disorders, has announced its participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. At this event, Alfred W. Sandrock, Jr., M.D., Ph.D., the CEO of Voyager, alongside other key members of the management team, will be involved in a pre-recorded fireside chat.
What to Expect from the Conference
The fireside chat will provide insights into the advancements and innovative solutions Voyager is developing to address various neurological conditions. This session will be available for on-demand viewing starting at 7:00 a.m. ET on a specified date. Interested parties can find access through the Investors section of Voyager’s website, where it will remain available for at least 30 days following the event.
Focus on Neurological Disease Treatment
Voyager Therapeutics is on a mission to transform the treatment landscape of neurological diseases, utilizing the intricate power of human genetics. The company’s robust pipeline includes various programs designed to tackle challenging conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia, among others. By leveraging their TRACER™ AAV capsid discovery platform, Voyager is making strides in creating novel capsids aimed at ensuring effective delivery of genetic medicines directly to the brain.
Collaborations and Partnerships
Voyager's initiatives are reinforced through strategic collaborations with noteworthy partners such as Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, and Neurocrine Biosciences. These partnerships enhance Voyager's capabilities, allowing the exploration of new avenues for combating some of the most challenging neurological diseases.
About Voyager Therapeutics
Founded to advance the treatment landscape for neurological disorders, Voyager Therapeutics aims to modify disease progression and ultimately find cures. This vision drives the company forward as it continues its research and development efforts in the field.
Contact Information
For additional information, individuals can reach out to Trista Morrison at tmorrison@vygr.com. For investor relations, Sarah McCabe can be contacted at smccabe@jpa.com. Media inquiries can be directed to Brooke Shenkin at brooke@scientpr.com.
Frequently Asked Questions
What is Voyager Therapeutics known for?
Voyager Therapeutics specializes in innovative treatments for neurological diseases through genetic therapies.
When will the pre-recorded fireside chat be available?
The chat will be accessible for on-demand viewing starting at 7:00 a.m. ET on a specified date.
What diseases is Voyager targeting?
Some of the diseases include Alzheimer's, Parkinson's, ALS, and Friedreich's ataxia.
Who is leading the chat for Voyager at the conference?
Dr. Alfred W. Sandrock, Jr., the CEO, will be leading the fireside chat.
How does Voyager's TRACER™ platform work?
The TRACER™ platform is utilized to discover novel AAV capsids that improve the delivery of genetic medicines to the brain.
